These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 27993796)

  • 1. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
    Matulonis UA; Wulf GM; Barry WT; Birrer M; Westin SN; Farooq S; Bell-McGuinn KM; Obermayer E; Whalen C; Spagnoletti T; Luo W; Liu H; Hok RC; Aghajanian C; Solit DB; Mills GB; Taylor BS; Won H; Berger MF; Palakurthi S; Liu J; Cantley LC; Winer E
    Ann Oncol; 2017 Mar; 28(3):512-518. PubMed ID: 27993796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
    Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
    Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M
    Br J Cancer; 2019 Feb; 120(3):279-285. PubMed ID: 30655615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer.
    Liu JF; Barry WT; Birrer M; Lee JM; Buckanovich RJ; Fleming GF; Rimel BJ; Buss MK; Nattam SR; Hurteau J; Luo W; Curtis J; Whalen C; Kohn EC; Ivy SP; Matulonis UA
    Ann Oncol; 2019 Apr; 30(4):551-557. PubMed ID: 30753272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM; Postel-Vinay S; Im SA; Park YH; Delord JP; Italiano A; Alexandre J; You B; Bastian S; Krebs MG; Wang D; Waqar SN; Lanasa M; Rhee J; Gao H; Rocher-Ros V; Jones EV; Gulati S; Coenen-Stass A; Kozarewa I; Lai Z; Angell HK; Opincar L; Herbolsheimer P; Kaufman B
    Lancet Oncol; 2020 Sep; 21(9):1155-1164. PubMed ID: 32771088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety.
    Matulonis UA; Penson RT; Domchek SM; Kaufman B; Shapira-Frommer R; Audeh MW; Kaye S; Molife LR; Gelmon KA; Robertson JD; Mann H; Ho TW; Coleman RL
    Ann Oncol; 2016 Jun; 27(6):1013-1019. PubMed ID: 26961146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
    Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
    Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer.
    Shah PD; Wethington SL; Pagan C; Latif N; Tanyi J; Martin LP; Morgan M; Burger RA; Haggerty A; Zarrin H; Rodriguez D; Domchek S; Drapkin R; Shih IM; Smith SA; Dean E; Gaillard S; Armstrong D; Torigian DA; Hwang WT; Giuntoli R; Simpkins F
    Gynecol Oncol; 2021 Nov; 163(2):246-253. PubMed ID: 34620496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DUETTE: a phase II randomized, multicenter study to investigate the efficacy and tolerability of a second maintenance treatment in patients with platinum-sensitive relapsed epithelial ovarian cancer, who have previously received poly(ADP-ribose) polymerase (PARP) inhibitor maintenance treatment.
    McMullen M; Karakasis K; Loembe B; Dean E; Parr G; Oza AM
    Int J Gynecol Cancer; 2020 Nov; 30(11):1824-1828. PubMed ID: 32878963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Do KT; Kochupurakkal B; Kelland S; de Jonge A; Hedglin J; Powers A; Quinn N; Gannon C; Vuong L; Parmar K; Lazaro JB; D'Andrea AD; Shapiro GI
    Clin Cancer Res; 2021 Sep; 27(17):4710-4716. PubMed ID: 34131002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

  • 16. EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Lheureux S; Oaknin A; Garg S; Bruce JP; Madariaga A; Dhani NC; Bowering V; White J; Accardi S; Tan Q; Braunstein M; Karakasis K; Cirlan I; Pedersen S; Li T; Fariñas-Madrid L; Lee YC; Liu ZA; Pugh TJ; Oza AM
    Clin Cancer Res; 2020 Aug; 26(16):4206-4215. PubMed ID: 32444417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM
    Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
    Poveda AM; Davidson R; Blakeley C; Milner A
    Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
    Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
    Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.